| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $8,508,015 | 19 | 100 |
| Cavanagh Bethany J | SVP, Finance and Treasurer | 0 | $0 | 4 | $309,728 | $-309,728 |
| Bellon Christine | Chief Legal Officer | 0 | $0 | 4 | $483,789 | $-483,789 |
| Simon Amy | Chief Medical Officer | 0 | $0 | 4 | $576,930 | $-576,930 |
| Ciaramella Giuseppe | President | 0 | $0 | 3 | $2.83M | $-2.83M |
| Evans John M. | CEO | 0 | $0 | 4 | $4.31M | $-4.31M |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Over the last 12 months, insiders at Beam Therapeutics Inc. have bought $0 and sold $8.51M worth of Beam Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Beam Therapeutics Inc. have bought $0 and sold $21.05M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2025-04-02 | Sale | Simon Amy | Chief Medical Officer | 20,997 0.0202% | $17.73 | $372,294 | -6.28% | |
| 2025-04-01 | Sale | Evans John M. | CEO | 30,663 0.032% | $18.35 | $562,684 | -1.77% | |
| 2025-04-01 | Sale | Ciaramella Giuseppe | President | 7,434 0.0077% | $18.35 | $136,418 | -1.77% | |
| 2025-04-01 | Sale | Bellon Christine | Chief Legal Officer | 5,674 0.0059% | $18.35 | $104,122 | -1.77% | |
| 2025-04-01 | Sale | Simon Amy | Chief Medical Officer | 9,566 0.01% | $18.35 | $175,542 | -1.77% | |
| 2025-04-01 | Sale | Cavanagh Bethany J | SVP, Finance and Treasurer | 3,015 0.0031% | $18.35 | $55,330 | -1.77% | |
| 2025-02-18 | Sale | Cavanagh Bethany J | SVP, Finance and Treasurer | 6,287 0.0082% | $35.00 | $220,045 | -45.07% | |
| 2025-02-14 | Sale | Bellon Christine | Chief Legal Officer | 10,000 0.0144% | $34.00 | $340,000 | -43.04% | |
| 2025-01-30 | Sale | Evans John M. | CEO | 30,000 0.0374% | $26.75 | $802,484 | -28.45% | |
| 2025-01-02 | Sale | Bellon Christine | Chief Legal Officer | 1,241 0.0015% | $24.68 | $30,628 | -10.73% | |
| 2025-01-02 | Sale | Cavanagh Bethany J | SVP, Finance and Treasurer | 1,117 0.0014% | $24.68 | $27,568 | -10.73% | |
| 2024-11-06 | Sale | Ciaramella Giuseppe | President | 51,110 0.0594% | $26.36 | $1.35M | -7.53% | |
| 2024-10-14 | Sale | Ciaramella Giuseppe | President | 51,110 0.0592% | $26.27 | $1.34M | -8.88% | |
| 2024-10-01 | Sale | Bellon Christine | Chief Legal Officer | 385 0.0004% | $23.48 | $9,040 | +2.65% | |
| 2024-10-01 | Sale | Cavanagh Bethany J | SVP, Finance and Treasurer | 289 0.0003% | $23.48 | $6,785 | +2.65% | |
| 2024-09-30 | Sale | Evans John M. | CEO | 60,000 0.0651% | $24.60 | $1.48M | -2.00% | |
| 2024-07-02 | Sale | Simon Amy | Chief Medical Officer | 748 0.0008% | $22.95 | $17,167 | +8.68% | |
| 2024-07-01 | Sale | Simon Amy | Chief Medical Officer | 502 0.0005% | $23.76 | $11,928 | +6.42% | |
| 2024-06-27 | Sale | Evans John M. | CEO | 60,000 0.0649% | $24.50 | $1.47M | +2.27% | |
| 2024-04-02 | Sale | Simon Amy | Chief Medical Officer | 16,530 0.0223% | $30.54 | $504,851 | -18.46% |
| Increased Positions | 143 | +65.6% | 23M | +28.3% |
| Decreased Positions | 84 | -38.53% | 3M | -4.24% |
| New Positions | 42 | New | 4M | New |
| Sold Out Positions | 35 | Sold Out | 1M | Sold Out |
| Total Postitions | 277 | +27.06% | 101M | +24.05% |
| Farallon Capital Management Llc | $166,760.00 | 8.16% | 8.24M | +31,000 | +0.38% | 2024-12-31 |
| Blackrock, Inc. | $163,998.00 | 8.02% | 8.1M | +430,717 | +5.61% | 2025-03-31 |
| Vanguard Group Inc | $154,269.00 | 7.55% | 7.62M | -222,617 | -2.84% | 2024-12-31 |
| Ark Investment Management Llc | $143,057.00 | 7% | 7.07M | +536,930 | +8.22% | 2024-12-31 |
| Arch Venture Management, Llc | $91,892.00 | 4.5% | 4.54M | -294,521 | -6.09% | 2024-12-31 |
| Sumitomo Mitsui Trust Group, Inc. | $86,361.00 | 4.22% | 4.27M | +309,260 | +7.81% | 2025-03-31 |
| Nikko Asset Management Americas, Inc. | $80,102.00 | 3.92% | 3.96M | +404,782 | +11.39% | 2024-12-31 |
| Fmr Llc | $67,142.00 | 3.28% | 3.32M | -894,223 | -21.23% | 2024-12-31 |
| State Street Corp | $62,286.00 | 3.05% | 3.08M | -852,180 | -21.69% | 2024-12-31 |
| Mwg Management Ltd. | $45,883.00 | 2.24% | 2.27M | 0 | 0% | 2024-12-31 |